ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0726

Optimizing Laboratory Medication Safety Monitoring in Patients with JIA to Advance Value-based Care

Julia Harris1, Leslie Favier2, Emily Fox3, Michael Holland3, Cara Hoffart3, Maria Ibarra3, Jordan Jones3, Luke Harris1 and Ashley Cooper3, 1Children's Mercy Kansas City, Overland Park, KS, 2Children's Mercy Kansas City, Leawood, KS, 3Children's Mercy Kansas City, Kansas City, MO

Meeting: ACR Convergence 2022

Keywords: Cost-Effectiveness, Drug toxicity, quality of care

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: Health Services Research Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Most children with juvenile idiopathic arthritis (JIA) are treated with medications that require medication safety monitoring labs. Recommended laboratory testing includes a creatinine level. However, 87.5% of our baseline visits had a basic metabolic panel (BMP) ordered instead of a creatinine alone. The difference in cost for ordering a serum creatinine versus a BMP is $31. The monetary difference in matched net revenue per unit, a better estimate of healthcare cost, is $12.09. This leads to increased healthcare costs to the hospital, payers, and families. Our project aim was to increase the ordering of a creatinine rather than a BMP in patients with non-systemic JIA needing methotrexate, leflunomide, and/or biologic medication safety lab monitoring in the Rheumatology Clinic from 12.5% to 80% in 8 months.

Methods: Education was provided to physicians on medication monitoring recommendations and cost differences between ordering a creatinine versus a BMP. We created process maps to analyze all the different ways that our patients get labs done. We incorporated this project in our pre-visit planning process. Our primary interventions involved updates to our electronic medical record (EMR): 1) addition of creatinine order to our ‘Favorites’, ‘Quick Orders’, and ‘Power Plan’ for internal orders; 2) addition of creatinine to our external laboratory order template; and 3) addition of creatinine to our infusion order sets. We did a sampling of 40 patients each month to collect data on our process measure, which was the percent of patients with JIA taking methotrexate, leflunomide, TNF inhibitors, abatacept, and/or tocilizumab who had a creatinine alone checked rather than a BMP for medication monitoring safety laboratory tests and created a run chart to review and track our performance over time.

Results: Our 6-months of baseline data from April to September 2021 had a median of 12.5% of visits having a creatinine alone checked instead of a BMP (Figure 1). Data from October to December 2021 were 65-78%, and we have consistently surpassed our goal of greater than 80% of patients having creatinine ordered since January 2022. There were no unintended consequences noted during our project.

Conclusion: Our project optimized laboratory medication safety monitoring in JIA patients by eliminating unnecessary tests to save costs and advance value-based care. Our primary interventions of education and EMR modifications allowed for standardization of laboratory test ordering. Some physicians in our group have expanded this project with other changes to their laboratory test ordering practice that could lead to decreased cost without sacrificing patient safety.

Supporting image 1

Run chart demonstrating the percent of JIA patients with creatinine ordered instead of BMP. The blue line represents the monthly data, and the black line is the baseline median.


Disclosures: J. Harris, None; L. Favier, None; E. Fox, None; M. Holland, None; C. Hoffart, None; M. Ibarra, None; J. Jones, None; L. Harris, None; A. Cooper, None.

To cite this abstract in AMA style:

Harris J, Favier L, Fox E, Holland M, Hoffart C, Ibarra M, Jones J, Harris L, Cooper A. Optimizing Laboratory Medication Safety Monitoring in Patients with JIA to Advance Value-based Care [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/optimizing-laboratory-medication-safety-monitoring-in-patients-with-jia-to-advance-value-based-care/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/optimizing-laboratory-medication-safety-monitoring-in-patients-with-jia-to-advance-value-based-care/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology